RxDoctor Payments Data

Ronetta Marhoover, NP

Family · van Wert, OHNPI 1871800698

Payments from drug & device makers

$1,214in general payments, 2019–2025

Across 29 payments — averaging $41.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$299
  • Pfizer$134
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$117
  • Amgen$114
  • Cvrx, Inc.$109
  • Scpharmaceuticals Inc.$109
  • plus $331 from 5 others

What the payments were for

  • Food & beverage$1,11392%
  • Education$1008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,214 in reported general payments places this provider in the 70th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$33,898
Medicare patients
280
Services billed
408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan189$192,814
EliquisApixaban186$129,340
JardianceEmpagliflozin85$65,774
FarxigaDapagliflozin Propanediol99$64,735
XareltoRivaroxaban32$23,665
Torsemide193$4,742
Isosorbide Dinitrate22$1,223
Atorvastatin Calcium184$1,131
Carvedilol229$1,093
Potassium Chloride94$1,080
Metoprolol Succinate135$1,039
Spironolactone207$998
Furosemide256$882
Bumetanide18$836
Ondansetron Hcl14$710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$72$192,814189 claims
PfizerEliquis$134$129,340186 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,812 family providers in Ohio.

Other family in van Wert

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →